PAIOF (Paion AG) Total Stockholders Equity: $-3.32 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAIOF Paion AG PAIOF
10 GF Score
Price $0.07
View Full Analysis

What is Paion AG Total Stockholders Equity?

Paion AG PAIOF 10 Total Stockholders Equity is $-3.32 Mil as of Jun. 2023. GuruFocus rates PAIOF with a GF Score™ of 10/100.

Paion AG's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-3.32 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Paion AG's Book Value per Share for the quarter that ended in Jun. 2023 was $-0.47. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Paion AG's Debt-to-Equity for the quarter that ended in Jun. 2023 was -6.93.


Paion AG  (OTCPK:PAIOF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Paion AG's Book Value per Share for the quarter that ended in Jun. 2023 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Paion AG's Debt-to-Equity for the quarter that ended in Jun. 2023 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paion AG Total Stockholders Equity Related Terms


Paion AG Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Paion AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion AG Total Stockholders Equity Chart

Paion AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.69 16.37 25.90 7.91 7.01

Paion AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.95 7.91 17.78 7.01 -3.32
PAIOF
10GF Score
Paion AG PAIOF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-3.32 Mil mean?
Paion AG (PAIOF) has a Total Stockholders Equity of $-3.32 Mil as of Jun. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Paion AG and its competitors.
Is Paion AG's Total Stockholders Equity too high?
Paion AG's current Total Stockholders Equity is $-3.32 Mil. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Total Stockholders Equity compare to ZTS and NBIX?
Paion AG's Total Stockholders Equity of $-3.32 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Paion AG and its competitors. Paion AG's current Total Stockholders Equity is $-3.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Total Stockholders Equity of $-3.32 Mil. The current Total Stockholders Equity is $-3.32 Mil. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Paion AG (PAIOF), the current Total Stockholders Equity is $-3.32 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paion AG Business Description

Address Heussstrasse 25, Aachen, DEU, 52078
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score

Get the complete analysis for PAIOF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price